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Background: The preferential use of primary iliac stenting vs selective stenting is controversial. This study compares the
early and late clinical outcomes of primary vs selective iliac stenting at our institution.
Methods: A total of 110 consecutive patients with iliac stenosis (149 lesions) underwent primary stenting over a recent
5-year period (primary stent group). The early technical and clinical success and late clinical outcomes were compared
with 41 patients (41 iliac lesions) who had percutaneous transluminal angioplasty (PTA) followed by selective stenting
for suboptimal PTA (selective stent group). All patients were evaluated clinically and by duplex scanning with
ankle-brachial indexes at 1, 6, and 12 months and every 12 months thereafter.
Results: The perioperative complication rate for the primary stent group was 2.7% (three minor hematomas) vs 24% for
the selective stent group (P < .0001). The overall early clinical success rate was 97% for the primary stent group vs 83%
for the selective stent group (P  .002), however, the rate was 100% for short stenosis (A and B lesions <5 cm TASC
classification) in both groups; in contrast to 93% for the primary stent group vs 46% for the selective stent group for
longer stenoses (TASC - C and D lesions, P  .0003). The overall late clinical success was comparable for both groups:
88% for the primary stent group vs 80% for the selective stent group, however, this rate was superior for the longer lesions
in the primary stent group, 84% vs 46% (P .007). The primary patency rates at 1, 2, 3, and 5 years were 98%, 94%, 87%,
and 77% for the primary stent group vs 83%, 78%, 69%, and 69% for the selective stent group (P .030). These rates were
comparable in both groups for shorter lesions: 100%, 98%, 98%, and 87% for the primary stent group vs 100%, 93%, 85%,
and 85% for the selective stent group (P  .637). However, they were superior for the primary stent group in longer
lesions: 96%, 90%, and 72% vs 46%, 46%, and 28% for the selective stent group at 1, 2, and 3 years (P < .0001).
Conclusions: The overall early clinical success rate was superior for the primary stent group. However, the initial (early)
and late clinical success rates were comparable for short lesions (TASC - A and B lesions), but were inferior in selective
stenting for longer lesions (TASC - C and D). Therefore, primary stenting should be offered to all TASC - C and D
lesions. ( J Vasc Surg 2007;46:965-70.)Iliac artery percutaneous transluminal angioplasty (PTA)
has become standard therapy, particularly for short lesions
(Transatlantic InterSociety Consensus [TASC] - A & B) and
some selected long lesions (TASC - C & D), with a long-
term patency rate range of 60% to 90% over 3 to 5
years.1-13 However, the success of iliac PTA is generally
reduced by initial residual stenosis and late restenosis. Iliac
stent placement is indicated for initial suboptimal PTA
results which include: residual stenosis of 30%, as mea-
sured by angiography; a mean pressure gradient of5 mm
Hg across the treated site; and/or extensive intimal dissec-
tion.14-18 Indeed, several studies reported improvement of
the immediate hemodynamic and angiographic results of
iliac PTA in patients with suboptimal results.14-18 In con-
trast, the efficacy of stents is widely recognized as limited in
the long-term, secondary to narrowing of the luminal di-
ameter of the stents caused by intimal proliferation.19
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doi:10.1016/j.jvs.2007.07.027The Dutch randomized iliac study which demonstrate
equivalent results of primary vs selective stenting of iliac
artery lesions is the only randomized study to compare the
efficacy these two approaches in the endovascular treatment
of iliac artery occlusive disease.20,21 However, in spite of
the equivalency of primary and selective stenting in the
Dutch study, the preferential use of primary iliac stenting vs
PTAwith selective stenting is still controversial, particularly
for TASC C and D lesions. Many authorities advocate
routine primary iliac stenting after an otherwise uncompli-
cated PTA of such lesions in an attempt to improve the
long-term results.22-24 Because of the initial angiographic
and hemodynamic advantages of iliac stent insertion, and
the significant number of our earlier patients with TASC -
C and D lesions who failed with PTA only, we adopted a
policy of routine primary iliac stenting in the last few years
instead of selective stenting. This study compares the early
and late clinical outcome of primary iliac stenting vs iliac
PTA with selective stenting in our institution over the last
several years.
PATIENT POPULATION AND METHODS
One hundred and ten consecutive patients with iliac
artery stenosis (149 iliac lesions) underwent iliac PTA with
primary stenting over a recent 5-year period (July 2000 to
June 2005; primary stent group). The early technical and
clinical success and late clinical outcomes of these patients
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PTA followed by selective stenting for only patients with
suboptimal results that were done 5 years prior to that (July
1994 to June 1999; selective stent group). This earlier
group included both all patients with successful PTA only
and those patients undergoing selective stenting, with se-
lective stenting being indicated for suboptimal PTA results
including residual stenosis of 30%, the presence of a
pressure gradient of 5 to 10 mm Hg, or the presence of
gross long dissection after PTA. All procedures were done
by the senior author (AFA). All primary stent patients were
treated in the Circulatory Dynamics Laboratory (CDL, an
independent vascular invasive laboratory suite outside the
operating room). The earlier group (selective stent group)
was treated either in the operating room (earlier) using a
special vascular suite equipped with an ISS imaging system
(International Surgical System, Phoenix, Ariz) or later in
the CDL lab. The study protocol was approved by our local
Institutional Review Board.
Patients’ clinical evaluations. All patients were
judged to be candidates for PTA and/or stenting if they
reported disabling claudication, had failed medical therapy,
or demonstrated rest pain or ischemic tissue loss. All pa-
tients underwent preoperative duplex ultrasound examina-
tions and ankle-brachial indexes prior to angiography to
determine the need for iliac PTA. The clinical/demo-
graphic characteristics for both groups were comparable
Table I. Demographic/clinical characteristics
Primary TASC
A & B lesions
(n  61)
Selective
A & B l
(n 
Age (mean) 62.9 (10 y) 72.6 (
Gender
Male 28 (46%) 12 (4
Female 33 (54%) 16 (5
Smoking 34 (56%) 18 (6
Diabetes mellitus 23 (38%) 8 (2
Hypertension 51 (84%) 20 (7
Hypercholesterolemia 28 (46%) 11 (3
Coronary artery disease 34 (56%) 17 (6
NS, Not significant.
Table II. Indications of PTA/stenting
Indications
Primary
stenting
Selective
stenting P value
Stage I PVD
(disabling claudication) 41 (37%) 14 (34%) NS
Stage II PVD
(critical ischemia: rest
pain) 51 (46%) 18 (44%) NS
Stage III PVD
(critical ischemia:
trophic changes) 18 (16%) 9 (22%) NS
NS, Not significant; PTA, percutaneous transluminal angioplasty; PVD,
peripheral vascular disease.except for the mean age and hypertension (see Table I).The indications for PTA/stenting were similar in both the
primary stenting and the selective stenting groups, as
shown in Table II. The iliac lesion distribution and status of
the superficial femoral artery is shown in Table III. As noted
in this table, there were no statistically significant differ-
ences between the distribution of the disease, whether
common iliac vs external iliac; in both groups, however, the
primary stenting group was less likely to have a superficial
femoral artery occlusion (P  .025).
PTA/stent techniques. After completion of diag-
nostic angiography, the lesion was crossed with a guide-
wire and the pressure gradient across the lesion was
measured before and after PTA. Low-profile Meditech
ultra-thin balloon catheters (Boston Scientific, Water-
town, Mass) in 2 to 4 cm lengths and 7 to 12 mm in
diameter were used, according to the length of the
lesion and the size of the artery, as judged by intraoper-
ative arteriograms. Primary stenting was done using
self-expanding Smart stents (Cordis, Johnson & John-
son, Warren, NJ). Both Wall stents (Boston Scientific,
Watertown, Mass) and Palmaz stents (Cordis, Johnson
& Johnson, Warren, NJ) were used in the selective stent
group. All patients were given 325 mg of oral aspirin
prior to the procedure, 325 mg of aspirin and 300 mg of
Plavix (clopidogrel, Bristol-Myers Squibb, New York,
NY) immediately postoperatively, 75 mg of Plavix for 6
weeks postoperatively and 325 mg of aspirin indefinitely.
Patients were generally discharged within 24 hours after
Primary TASC
C & D lesions
(n  49)
Selective TASC
C & D lesions
(n  13) P value
64.5 (11.5y) 68.5 (8.8y) .0007
29 (59%) 7 (54%) NS
20 (41%) 6 (46%) NS
28 (57%) 10 (77%) NS
20 (41%) 5 (39%) NS
41 (84%) 6 (46%) .015
20 (41%) 7 (54%) NS
26 (53%) 8 (62%) NS
Table III. Iliac lesion distribution and superficial femoral
artery status
Primary
stenting
Selective
stenting P value
Common iliac artery 89 (60%) 29 (71%) P  .47
External iliac artery 31 (21%) 7 (17%)
Combined common and
external iliac arteries 29 (19%) 5 (12%)
No SFA occlusion 71 (65%) 21 (51%) P  .025
SFA occlusion 11 (10%) 12 (29%)
Bilateral SFA occlusion 28 (25%) 8 (20%)
SFA, superficial femoral artery.TASC
esions
28)
9.6y)
3%)
7%)
4%)
9%)
1%)
9%)
1%)the procedure.
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lowed clinically and PTA/stent patency was assessed by
duplex ultrasound examination and measurement of an-
kle/brachial indexes at 1 month, 6 months, 12 months,
and every year thereafter. Arteriograms were obtained
when new symptoms developed, a 15% drop in the ankle-
brachial index was detected, or a duplex ultrasound exam-
ination documented50% stenosis or occlusion of the iliac
PTA/stenting site. The mean follow-up was 24 months
(range: 1 to 81 months) for the primary stenting group vs
34 months (range: 1 to 66 months) for the selective stent-
ing group. Every effort was made to comply with the
Reporting Standards for the Lower Extremity Endovascu-
lar Procedures as advocated by the Ad Hoc Committee of
the Society of Vascular Surgery.25
Study design and statistical analysis. The following
terms are used in this manuscript: early clinical success (30
days perioperatively) is defined as symptom resolution or
improvement by defined clinical criteria, an increase of the
ankle/brachial index by 0.15, and the presence of resid-
ual stenosis of30% of a normal diameter on imaging. Late
continued clinical success is defined when sustained im-
provement in each of the three categories was documented
(clinical, hemodynamic, and anatomic success). Clinical
patency of the PTA/stent is defined if the patient has
sustained objective hemodynamic improvement and pa-
tency on duplex ultrasound imaging.
Lesions treated were classified according to the TASC
classification.8 Lesions were then combined into groups of
short lesions consisting of A and B lesions (5 cm) and
long lesions consisting of C and D lesions (5 to 10 cm,
and 10 cm) for analysis. There were 28 TASC - A and B
lesions in the selective stenting group, 24 of which had
successful PTA only and four which required selective
stenting; and 13 TASC - C and D lesions, 12 of which
required selective stenting. In the primary stenting group,
there were 61 TASC - A and B lesions and 49 TASC - C and
D lesions.
Standard analysis was done using chi square and
ANOVA (with Bonferroni post tests) for numerical data.
Association of hemodynamic, anatomic, and symptomatic
improvement in the segment of a treated artery and the
placement of the stent was determined by chi square anal-
ysis. The Kolmogorov-Smirnov and Anderson-Darling
goodness of fit tests were run to assure normal distribution
of the data. All four groups (TASC A and B lesions and
TASC C and D lesions - Primary Stenting Group, TASC A
and B lesions, TASC C and D lesions - Selective Stenting
Group) were found to be normally distributed (using both
test methods) at a 95% confidence level. Primary patency of
the PTA site was analyzed using the Kaplan Meier lifetable
analysis and the log-rank and Wilcoxon analysis for primary
vs selective stenting comparison was applied.
RESULTS
Perioperative technical outcomes and complications.
The immediate technical success rate was 100% for both
groups. The perioperative complication rate for the primaryiliac stenting group was 2.7% (3 out of 110 patients), which
included threeminor hematomas. For the selective stenting
group, the perioperative complication rate was 24% (10 out
of 41 patients) (P  .0001). These 10 patients included:
two patients with short (TASC - A and B) lesions, one who
had a postoperative deep vein thrombosis and one who had
bleeding requiring operative intervention (with an un-
eventful recovery); and eight patients with longer (TASC -
C and D) lesions, including one patient who had superficial
cellulitis that was treated with antibiotics and seven who
had early postprocedure iliac artery thrombosis. Two of
these occurred within 24 hours and both were treated with
thrombectomy while the five other patients had thrombosis
within 1 to 21 days and were treated with thrombectomy
and/or bypasses. There were no perioperative deaths
and/or amputations in either group.
Early and late clinical outcomes. The overall early
clinical success rate was 97% for the primary stenting
group vs 83% for the selective stenting group (P  .002)
Table IV). However, the early clinical success rate was
100% for short stenoses (TASC - A and B lesions) in both
groups vs 93% for primary stenting and 46% for selective
stenting for longer stenoses (TASC - C and D lesions,
P  .003). The overall late clinical success rates were
comparable for both groups: 88% for primary stenting vs
80% for selective stenting and the late clinical success was
also comparable for the shorter stenoses: 95% for primary
stenting vs 96% for selective stenting. In contrast, the
late clinical success rate was again better in the primary
stenting group; for longer stenosis: 84% in the primary
stenting group vs 46% for selective stenting group (P 
.007). The limb salvage rate was also better after primary
stenting; 100% for the primary stenting group vs 93% for
the selective stenting group (P  .02). There was no
significant relationship between any risk factors (comor-
bidities), indications for PTA/stenting, or the status of
the superficial femoral artery (occlusion vs patency) and
early or late clinical success.
Late primary patency. The primary patency rates at
Table IV. Early and late clinical success
Success (N) % P value
Early clinical success
Primary stenting (n  149) 145 97 .002
Selective stenting (n  41) 34 83
Primary A & B lesions (n  92) 92 100 NS
Selective A & B lesions (n  28) 28 100
Primary C & D lesions (n  57) 53 93 .0003
Selective C & D lesions (n  13) 6 46
Late clinical success
Primary stenting (n  142) 125 88 NS
Selective stenting (n  41) 33 80
Primary A & B lesions (n  92) 87 95 NS
Selective A & B lesions (n  28) 27 96
Primary C & D lesions (n  57) 48 84 .007
Selective C & D lesions (n  13) 6 46
NS, Not significant.1, 2, 3, and 5 years were: 98%, 94%, 87%, and 77% for the
JOURNAL OF VASCULAR SURGERY
November 2007968 AbuRahma et alprimary stenting group vs 83%, 78%, 69%, and 69% for
the selective stenting group (log rank P value 0.03,
Wilcoxon P value  .0001, Fig 1 and Table V, online
only). The primary patency rates for patients treated for
shorter stenoses (TASC - A and B lesions) were compa-
rable regardless of treatment type: 100%, 98%, 98%, and
87% for the primary stenting group vs 100%, 93%, 85%,
and 85% for selective stenting group (log rank P value
.637, Wilcoxon P value .132, and Fig 2 and Table VI,
online only). In contrast, the primary patency rates for
the patients treated for longer stenoses (TASC - C and D
lesions) were significantly better for patients undergoing
primary stenting: 96%, 90%, and 72% for primary stent-
ing vs 46%, 46%, and 28% for selective stenting at 1, 2,
and 3 years, respectively (log rank P value  .0001 and
Wilcoxon P value  .0001, Fig 3 and Table VII, online
Fig 1. Overall primary patency for primary iliac stenting vs selec-
tive iliac stenting.
Fig 2. Primary patency curve for primary iliac stenting vs selective iliac
stenting for short stenosis (TASC - A and B lesions).only).DISCUSSION
The controversial aspects of iliac PTA and stenting that
we tried to address in this study deal with whether stenting
should be performed primarily, or only selectively, based on
certain criteria, and also which iliac lesions, based on TASC
stratification, are amenable to PTA/stenting. The Dutch
randomized trial (primary stenting vs selective stenting)
showed that selective iliac artery stenting was as effective as
primary stenting.21 However, the Dutch randomized trial
excluded patients with stenosis 10 cm (TASC- D) or
occlusion 5 cm.21 Similarly, Cambria et al advocated PTA
with selective stenting due to an inability to show a signif-
icant improvement in patency rates with primary stenting, a
high overall complication rate of 18%, and resultant major
amputations in 12% of 141 patients.28 However, again the
average length of stenosis treated in their series was 3.3 
0.1 cm, which was similar to our observation of comparable
early and late clinical success with both primary and selec-
tive stenting of such short lesions. Also, the overall compli-
cation rates in a recent series with primary stenting have
been lower (1.4% to 4.8%)29-32 and the overall complica-
tion rate for primary stenting in our series was 2.7%.
Despite the results from the Dutch randomized trial,
many authors advocate the use of primary stenting for
endovascular treatment of iliac artery lesions.22-24 In addi-
tion, a meta-analysis by Bosch and Hunink comparing six
series of PTA alone (1300 patients) and eight series of PTA
with stent placement (816 patients) published after 1990,
showed that routine PTA/stenting was associated with
better 4-year patency rates than PTA alone for patients with
claudication or critical ischemia. Furthermore, a 39% re-
duction of the risk of long-term failure after stent place-
ment was demonstrated.26
Our data further supports the contention that
shorter lesions (TASC- A and B) can be adequately
treated with either primary or selective stenting follow-
ing PTA. The early clinical success rate for short lesions
Fig 3. Primary patency curve for primary iliac stenting vs selective iliac
stenting for long stenosis (TASC - C andD lesions).after both types of treatment was 100%. The late clinical
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primary and selective stenting, 95% and 96%, respec-
tively. Similarly, Galaria et al reported on their retrospec-
tive 10-year review of patients undergoing PTA with or
without stenting (based on surgeon preference) and
concluded that primary PTA and selective stenting was a
safe and durable intervention for TASC - A and B
lesions.13
The presence of external iliac artery disease and in-
creased lesion length (TASC C and D) have been reported
to adversely affect the outcomes from iliac PTA with selec-
tive stenting.5,12,13 Becquemin et al observed a poorer
2-year patency with selective stenting of lesions 3 cm
length (69.7%  6.5%), suggesting that primary stenting
might have improved their results.5 Silva et al, using a
protocol of selective stenting, also observed that the length
of the lesion was a predictor of the clinical success, with
lesions5 cm showing poorer initial and continued success
rates, compared with lesions 5 cm (82% and 62% vs 96%
and 82%, respectively).27 However, few studies have specif-
ically compared the use of stenting, selective or primary, for
longer (TASC - C and D) lesions.
The superior primary patency rates and clinical success
rates observed in our series for TASC - C and D lesions
treated by primary stenting were also observed by Leville et
al.34 In their study, 89 patients underwent 92 procedures,
30 TASC - C lesions (33.7%) and 37 TASC - D lesions
(41.6%), with primary and secondary patency rates at 3
years of 73% and 93% for TASC - C lesions and 80% and
83% for TASC - D lesions.34 Similarly, De Roeck et al33
reported the results of 38 patients who underwent percu-
taneous recanalization of an occluded iliac artery with
subsequent stenting for TASC - B lesions in 12 patients,
TASC - C in 10 patients, and TASC - D in 16 patients. The
technical success rate was 97% and the 30-daymortality rate
was 2.7%. The primary patency rates at 1, 3, and 5 years
were 94%, 89%, and 77%, respectively. Three re-occlusions
(8.1%) and one restenosis (2.7%) were observed during
follow-up, at a mean of 26 months. They concluded that
long-term results of iliac recanalization were excellent with-
out major complications, if the procedure was technically
successful. Early and late clinical success notes for such
longer, complex lesions were also delineated to show supe-
riority of primary stenting over selective stenting in our
series.
Our study has several limitations. The inferior outcome
of the selective stent group can be partially attributed to our
early operative experience and the result of seven cases of
perioperative thrombosis in the TASC - C and D lesions in
the selective stenting group. The PTAs that were done for
these extensive lesions in the early series may have caused
extensive dissection or arterial damage prior to the stenting,
which initiated the perioperative thrombosis. These pa-
tients may have also been inadequately treated with stent-
ing as only one stent was placed in each patient in the early
series. Another limitation of this study is the fact that two
types of stents (Palmaz stainless steel stents and Wallstents)
were used in the selective stenting group while only theSmart Nitinol stent was used in the primary stenting group,
which may or may not explain the difference in the results
of these two series. Furthermore, a significant number of
patients in the selective study group who were lost for
follow-up at the later stage since they were done several
years earlier, which may have impacted the results. Addi-
tionally, the groups are different in regards to age distribu-
tion, and the small sample size of the selective stenting
group may have affected our statistical analysis. Finally, it
should be noted that the interpretation of our results
cannot be taken in the same context of the Dutch study,
since 92% of the patients in the Dutch study were treated
for intermittent claudication, while only one-third of our
patients had PTA and/or PTA/stenting for claudication.
In conclusion, the early clinical success rate after endo-
vascular treatment of iliac artery lesions was superior for
patients undergoing the primary stenting. However, the
early and late clinical success rates were comparable treat-
ment of short lesions (TASC - A and B lesions) regardless of
whether primary or selective stenting was done, but were
inferior for selective stenting of longer lesions (TASC - C
and D). Therefore, primary stenting of the iliac artery
lesions may be of value in patients with TASC - C and D
lesions.
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Volume 46, Number 5 AbuRahma et al 970.e1Table V, online only. Primary patency: Primary stenting
Primary stenting
Time
(mos.)
No. at
risk
No.
failed
No.
censored Patency
0 149 0 3 100%
1 120 2 52 100%
12 85 1 14 98%
24 56 2 9 94%
36 30 1 5 87%
48 16 0 6 77%
60 4 1 2 77%
Log-rank P value .030; Wilcoxon P value .0001.vs selective stenting (whole group)
Selective stenting
St.
error
No. at
risk
No.
failed
No.
censored Patency
St.
error
0% 41 0 0 100% 0%
0% 41 7 0 100% 0%
1% 34 1 1 83% 6%
3% 27 2 4 78% 7%
4% 16 0 5 69% 8%
7% 11 0 1 69% 8%
7% 5 0 2 69% 8%
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November 2007970.e2 AbuRahma et alTable VI, online only. Primary patency: Primary stenting vs selective stenting for short stenosis (TASC - A and B
lesions)
Primary stenting Selective stenting
Time
(mos.)
No. at
risk
No.
failed
No.
Censored Patency
St.
error
No. at
risk
No.
failed
No.
censored Patency
St.
error
0 92 0 1 100% 0% 28 0 0 100% 0%
1 72 0 38 100% 0% 28 0 0 100% 0%
12 49 0 9 100% 0% 28 1 1 100% 0%
24 32 0 6 98% 3% 24 2 3 93% 5%
36 20 1 3 98% 3% 15 0 4 85% 7%
48 11 0 4 87% 8% 11 0 1 85% 7%
60 4 1 2 87% 8% 5 0 2 85% 7%Log rank P value .637; Wilcoxon P value .132.Table VII, online only. Primary patency: Primary stenting vs. selective stenting for long stenosis (TASC - C and D
lesions)
Primary stenting Selective stenting
Time
(mos.)
No. at
risk
No.
failed
No.
Censored Patency
St.
error
No. at
risk
No.
failed
No.
censored Patency
St.
error
0 57 0 2 100% 0% 13 0 0 100% 0%
1 48 2 14 100% 0% 13 7 0 100% 0%
12 37 1 5 96% 3% 6 0 0 46% 5%
24 24 2 3 90% 5% 4 0 1 46% 5%
36 10 0 2 72% 9% 1 0 1 28% 7%
48 5 0 2 63% 12%
60Log rank P value .0001; Wilcoxon P value .0001.
